MedTrace Logo

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

NCT05595447 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-03-12

No results posted yet for this study

Summary

The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.

What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade

1?

Conditions

  • Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Relapsed Hodgkin's Disease, Adult

Interventions

DRUG

Brentuximab Vedotin 50 MG [Adcetris]

Brentuximab plus blocked PD-1 plus ASCT plus maintenance Brentuximab plus blocked PD-1

Sponsors & Collaborators

  • Universidad de Guanajuato

    collaborator OTHER

  • Hospital Regional de Alta Especialidad del Bajio

    lead OTHER

Principal Investigators

  • Lauro Amador Medina · Hospital regional Alta especialidad Bajío

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-18
Primary Completion
2025-10-18
Completion
2025-10-18

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05595447 on ClinicalTrials.gov